Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
22:50 - 23:00 | Presenter: Yun Fan
- Abstract
This abstract is currently under embargo and will be released during the conference.
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-014 - Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Presenter: Caicun Zhou- Abstract
Loading... -
+
EP08.01-032 - Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-033 - ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-042 - NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Presenter: Ying Cheng- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Presenter: James Chih-Hsin Yang- Abstract
Loading... -
+
EP08.02-051 - High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Presenter: Ying Cheng- Abstract
Loading... -
+
EP08.02-092 - Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Presenter: Na Li- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- 08:30 - 10:20
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Plenary
- Track: N/A
- Moderators:Heather Wakelee, Eric Lim
-
+
PL03.09 - IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Presenter: ENRIQUETA FELIP- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
12:07 - 12:12 | Presenter: Yun Fan
- Abstract
Loading...
